GMDAQ — Gamida Cell Share Price
0.000.00%
Last trade - 00:00- $2.62m
- $35.61m
- $1.78m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -94.87% | ||
| Return on Equity | n/a | ||
| Operating Margin | -4094.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 1.78 | 15.68 | 139.26 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
Directors
- Robert Blum NEC (57)
- Julian Adams CEO (66)
- Shai Lankry CFO (44)
- Michele Korfin COO (49)
- Tracey Lodie CSO (51)
- Joshua Hamermesh OTH (48)
- Ronit Simantov OTH (56)
- Jas Uppal OTH (53)
- Anat Cohen-Dayag DRC (54)
- Naama Halevi-Davidov DRC
- Stephen Wills IND (64)
- Nurit Benjamini NID (54)
- David Fox NID (63)
- Ofer Gonen NID (48)
- Kenneth Moch NID (66)
- Michael Perry NID (61)
- Shawn Tomasello NID (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 17th, 1998
- Public Since
- October 26th, 2018
- No. of Shareholders
- 201
- No. of Employees
- 145
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 154,013,109
- Address
- 12 Leshem Street, KIRYAT GAT, 82584120
- Web
- https://www.gamida-cell.com/
- Phone
- +972 26595666
- Contact
- Heather Divecchia
- Auditors
- Kost, Forer, Gabbay & Kasierer
Upcoming Events for GMDAQ
Similar to GMDAQ
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Gamida Cell share price?
As of Today at 20:46 UTC, shares in Gamida Cell are trading at $0.02. This share price information is delayed by 15 minutes.
How has the Gamida Cell share price performed this year?
Shares in Gamida Cell last closed at $0.02 and the price had moved by -99.14% over the past 365 days. In terms of relative price strength the Gamida Cell share price has underperformed the S&P500 Index by -99.29% over the past year.
What are the analyst and broker recommendations for Gamida Cell?
The overall consensus recommendation for Gamida Cell is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Gamida Cell dividend yield?
Gamida Cell does not currently pay a dividend.
Does Gamida Cell pay a dividend?
Gamida Cell does not currently pay a dividend.
When does Gamida Cell next pay dividends?
Gamida Cell does not currently pay a dividend.
How do I buy Gamida Cell shares?
To buy shares in Gamida Cell you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gamida Cell?
As of the previous close price of $0.02, shares in Gamida Cell had a market capitalisation of $2.62m.
Where are Gamida Cell shares listed?
Here are the trading details for Gamida Cell:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: GMDAQ
What kind of share is Gamida Cell?
Based on an overall assessment of its quality, value and momentum Gamida Cell is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gamida Cell share price forecast for 2024?
The analyst consensus target price for shares in Gamida Cell is $4.00. That is 23429.41% above the last closing price of $0.02.
Analysts covering Gamida Cell currently have a consensus Earnings Per Share (EPS) forecast of -$0.57 for the next financial year.
Find out moreWhat is the trend in the Gamida Cell share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gamida Cell. Over the past six months, its share price has underperformed the S&P500 Index by -95.42%.
As of the last closing price of $0.02, shares in Gamida Cell were trading -96.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gamida Cell PE Ratio?
The Gamida Cell PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gamida Cell?
Gamida Cell's management team is headed by:
- Robert Blum - NEC
- Julian Adams - CEO
- Shai Lankry - CFO
- Michele Korfin - COO
- Tracey Lodie - CSO
- Joshua Hamermesh - OTH
- Ronit Simantov - OTH
- Jas Uppal - OTH
- Anat Cohen-Dayag - DRC
- Naama Halevi-Davidov - DRC
- Stephen Wills - IND
- Nurit Benjamini - NID
- David Fox - NID
- Ofer Gonen - NID
- Kenneth Moch - NID
- Michael Perry - NID
- Shawn Tomasello - NID